Ono Pharmaceutical Co., Ltd., based in Osaka, Japan, has signed a licensing agreement with Ionis Pharmaceuticals, Inc. from Carlsbad, California, for sapablursen, a new RNA-targeted treatment for polycythemia vera (PV). This medication is currently being tested in adult patients with PV as part of the fully enrolled Phase 2 IMPRSSION study.
IONS has announced fourth-quarter results that exceeded expectations for both revenue and profit.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) will hold its Q4 2024 Earnings Conference Call on February 19, 2025, at 11:30 AM ET. The call will feature several company executives, including the CEO and CFO, as well as analysts from various financial institutions. Please note that this call is being recorded.
Ionis Pharmaceuticals reported better-than-expected earnings for the fourth quarter, but their forecast for 2025 was a bit lower than what analysts anticipated, resulting in a HOLD rating until more developments occur. The approval of TRYNGOLZA for FCS is a positive sign, but entering the bigger sHTG market by 2025 is essential for the company to become profitable and meet analyst predictions. With a solid cash reserve and a strong pipeline of over 40 RNA-targeted drugs, Ionis remains an interesting company to keep an eye on.
Ionis Pharmaceuticals (IONS 0.44%), a company known for its work in RNA-targeted drug discovery and development, shared its earnings results for the fourth quarter on February 19. The report showed that Ionis exceeded analysts' revenue predictions, earning $227 million instead of the expected $135 million.
The financial results for Ionis Pharmaceuticals (IONS) provide an overview of the company's performance for the quarter that ended in December 2024. It may also be helpful to compare some important metrics with Wall Street predictions and figures from the same period last year.
On Wednesday, Ionis Pharmaceuticals Inc (IONS) announced a fourth-quarter earnings per share (EPS) loss of $0.66, which is an increase from a loss of $0.06. This result was better than the expected loss of $1.10.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) shared key accomplishments from 2024 and discussed significant goals for 2025 in a recent announcement. The company is focused on enhancing value through various commercial, regulatory, and pipeline achievements. They also presented a clear strategy for maintaining positive cash flow in the future.
The FDA has approved IONS' Tryngolza, making it the first treatment for FCS to gain approval. This is also the first drug that the company fully owns to receive marketing authorization.
The U.S. Food and Drug Administration has given the green light to a drug from Ionis Pharmaceuticals for a rare genetic condition, marking it as the company's first fully-owned medication, according to the health regulator's website on Thursday.